Effect of Different VV ECMO Flows on Lung Perfusion Monitored by EIT

Recruiting

• Conditions: Critical Illness

• Registration Number: NCT05778292
• Lead Sponsor: Wuhan Union Hospital, China

Brief Summary

The purpose of this study is to investigate the feasibility of using electric impedance tomography (EIT) to monitor lung perfusion during veno-venous (VV) extracopreal membrane oxygenation (ECMO) support, as well as the effect of different ECMO flows on lung perfusion monitored by EIT.

Detailed Description

This is a monocentric obsevensional study that uses EIT to monitor lung perfusion during VV ECMO support and the effect of different ECMO flows on lung perfusion as measured by EIT. Patients on VV ECMO who meet the withdrawal criteria as determined by clinical experts will have their ECMO flow gradually reduced. EIT lung ventilation and perfusion monitoring were performed at various ECMO flows.

Study Timeline

• Study Start: 2023-01-01
• Study First Submitted: 2023-02-08
• Status Verified: 2023-03
• Study First Submitted QC: 2023-03-18
• Last Update Submitted: 2023-03-18
• Study First Posted: 2023-03-21
• Last Update Posted: 2023-03-21
• Primary Completion: 2024-12-31
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

1. Patients aged ≥ 18 and ≤ 70 years；
2. Patients supported with VV ECMO for respiratory failure；
3. Patients are intubated and mechanically ventilated.

Exclusion Criteria

1. EIT contraindications such as chest wound dressing, pacemaker installation, defibrillator, etc;
2. Patients who did not sign the informed consent form;
3. Pulmonary embolism;
4. Pneumothorax;
5. Medium to plenty of chest water;
6. Atrial fibrillation or other malignant arrhythmia leads to a decrease in cardiac output;
7. Refractory shock;
8. Severe chronic heart and lung disease has existed in the past;
9. BMI>35 kg/m2;
10. Intra-abdominal pressure >20mmHg.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Lung perfusion at different VV ECMO flows	up to 24hour	Effect of Different VV ECMO Flows (ECMO flow at 4.5L,3.5L,2.5L,1.5L, and after ECMO withdrawal) on lung perfusion distribution Monitored by EIT

Secondary Outcome Measures

Name	Time	Method
Lung ventilation at different VV ECMO flows	up to 24hour	Effect of Different VV ECMO Flows (ECMO flow at 4.5L,3.5L,2.5L,1.5L, and after ECMO withdrawal) on lung ventilation distribution monitored by EIT
Lung shunt region at different VV ECMO flows	up to 24hour	Effect of Different VV ECMO Flows (ECMO flow at 4.5L,3.5L,2.5L,1.5L, and after ECMO withdrawal) on lung shunt region monitored by EIT
Lung deadspace region at different VV ECMO flows	up to 24hour	Effect of Different VV ECMO Flows (ECMO flow at 4.5L,3.5L,2.5L,1.5L, and after ECMO withdrawal) on lung deadspace region monitored by EIT
Lung ventilation/perfusion matching at different VV ECMO flows	up to 24hour	Effect of Different VV ECMO Flows (ECMO flow at 4.5L,3.5L,2.5L,1.5L, and after ECMO withdrawal) on lung ventilation/perfusion matching monitored by EIT
Recirculation at different VV ECMO flows	up to 24hour	Recirculation at different VV ECMO flows (ECMO flow at 4.5L,3.5L,2.5L,and1.5L)

Trial Locations

Locations (1)

Xiaobo Yang; 🇨🇳 Wuhan, Hubei, China